---
title: Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study
nct_id: NCT02489760
overall_status: UNKNOWN
phase: PHASE4
sponsor: Chung Shan Medical University
study_type: INTERVENTIONAL
primary_condition: Ankylosing Spondylitis
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02489760.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02489760"
ct_last_update_post_date: 2016-01-20
last_seen_at: "2026-05-12T06:55:10.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study

**NCT ID:** [NCT02489760](https://clinicaltrials.gov/study/NCT02489760)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Chung Shan Medical University
- **Conditions:** Ankylosing Spondylitis
- **Start Date:** 2008-07
- **Completion Date:** 2016-10
- **CT.gov Last Update:** 2016-01-20

## Brief Summary

To determine the safety and efficacy of switch effects to adalimumab in etanercept-treated AS patients.

## Detailed Description

This single-centre, open-labeled randomized controlled study will evaluate the safety and efficacy of adalimumab in etanercept-treated Ankylosing Spondylitis(AS) patients.

Thirty patients will be enrolled and randomized equally into two arms.

Dosage and Administration：For standard dose(etanercept 50 mg weekly) treated patients, the treatment arm will receive adalimumab 40 mg subcutaneously biweekly for 8 weeks. The control arm will continue etanercept 25 mg subcutaneously twice a week for 8 weeks. At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.For half dose(etanercept 25 mg weekly) treated patients, the treatment arm will receive adalimumab 40 mg subcutaneously monthly for 8 weeks. The control arm will continue etanercept 25 mg subcutaneously weekly for 8 weeks. At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously monthly for another 8 weeks.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnosis of AS, as defined by 1984 Modified New York Criteria for AS.
* Stable background therapy as non-steroid anti-inflammatory for 2 weeks.
* Stable glucocorticoid for 4 weeks.
* Stable disease-modifying anti-rheumatic drugs, eg. sulphasalazine, methotrexate for 8 weeks.
* Stable anti-TNF biologics for 4 weeks.
* Written informed consent.

Exclusion Criteria:

* Serum creatinine ≥3.0 mg/dl.
* GPT≥5 times the laboratory's upper limit of normal.
* Pregnant or breast-feeding women.
```

## Arms

- **Adalimumab switch to Etanercept** (EXPERIMENTAL) — At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
- **Etanercept switch to Adalimumab** (EXPERIMENTAL) — At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.

## Interventions

- **Adalimumab** (BIOLOGICAL) — The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
- **Etanercept** (BIOLOGICAL) — The control arm will continue etanercept 25 mg subcutaneously twice a week

## Primary Outcomes

- **Bath AS disease activity index (BASDAI)** _(time frame: weeks 8)_ — The score of BASDAI on weeks 8

## Locations (1)

- Chung Shan Medical University Hospital, Taichung, Taiwan

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chung shan medical university hospital|taichung||taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02489760.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02489760*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*